Celltrion, Incorporation operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Celltrion, Incorporation with three other
companies in this sector in KOREA (SOUTH) :
Celltrion HealthCare Co Ltd
sales of 1.10 trillion Korean Won [US$928.04 million]
of which 100%
was Manufacture/Process/Sale of Medicine),
Green Cross Corporation
(1.37 trillion Korean Won [US$1.15 billion]
of which 84%
was Greencross), and
Samsung Biologics Co Ltd
(701.59 billion Korean Won [US$591.44 million]
of which 100%
was Biological Medicine Production).
Celltrion, Incorporation reported sales of 1.13 trillion Korean Won (US$951.29 million)
December of 2019.
increase of 14.9%
versus 2018, when the company's sales were 982.07 billion Korean Won .
Sales at Celltrion, Incorporation have increased during each of the previous five years
(and since 2014, sales have increased a total of 140%).
Sales of Chemical Business Division saw an increase
23.8% in 2019, from
139.47 billion Korean Won to 172.68 billion Korean Won .
Not all segments of Celltrion, Incorporation experienced an increase in sales in 2019:
sales of Other Segment fell 44.5% to 4.27 billion Korean Won .
(However, this segment's sales were only a very small portion of the company's overall sales).